Equities

Gamida Cell Ltd

GMDA:NMQ

Gamida Cell Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.0361
  • Today's Change-0.023 / -39.02%
  • Shares traded89.18m
  • 1 Year change-95.27%
  • Beta0.9452
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

  • Revenue in USD (TTM)673.00k
  • Net income in USD-76.95m
  • Incorporated1998
  • Employees143.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Eiger Biopharmaceuticals Inc14.67m-86.65m7.37m51.00------0.5024-1.96-1.960.3317-0.03610.14710.13167.76261,892.90-86.91-56.95-110.55-67.8398.24---590.80-1,242.443.24-28.501.04--11.05---185.33--50.52--
Enveric Biosciences Inc0.00-17.46m7.44m7.00--1.43-----8.15-8.150.000.71420.00----0.00-144.99-104.94-207.98-156.88-------243.54----0.00------7.14------
Pasithea Therapeutics Corp240.71k-15.59m7.45m15.00--0.2625--30.95-12.41-12.750.19127.230.006----16,047.33-38.86---40.66--100.54---6,478.41------0.00--3,130.81---541.19------
Manuka Inc671.00k-1.14m7.56m4.00------11.27-0.0128-0.01280.0066-0.01242.410.941237.28167,750.00-410.43-463.75----88.08---170.04-732.150.0194-----------854.23------
Aquabounty Technologies Inc2.37m-25.20m7.66m100.00--0.0442--3.23-6.95-6.950.652645.020.01147.43--23,703.50-12.14-15.91-13.03-16.53-534.21-637.66-1,063.23-1,793.571.80-94.870.0469--167.01125.940.7409--28.79--
First Wave BioPharma Inc0.00-15.91m7.80m10.00--0.811-----194.33-194.330.004.870.00----0.00-296.61-289.07-2,246.39-1,505.45-----------955.300.00------82.28------
Longeveron Inc709.00k-22.21m7.82m23.00--7.33--11.03-10.18-10.180.32620.42450.0359--4.3130,826.09-108.45-63.15-139.35-75.6831.1733.70-3,020.17-441.02----0.00---41.98-19.78-17.92--26.80--
Gamida Cell Ltd673.00k-76.95m7.85m143.00--20.45--11.67-0.8936-0.89360.00710.00290.0058----4,706.29-66.32-60.47-81.56-71.296.98---11,434.03--3.20--0.9953------11.60--73.69--
CeCors Inc-100.00bn-100.00bn7.87m6.00---------------0.0163------------------------------------22.70------
Plus Therapeutics Inc (USA)4.91m-13.32m7.91m20.00------1.61-4.51-4.511.57-0.30330.2787----245,650.00-75.54-59.18-210.10-133.04-----271.04-470.45----1.51--2,093.30-5.8934.32--3.77--
Lixte Biotechnology Holdings Inc0.00-5.09m7.92m3.00--16.00-----2.77-2.770.001.780.00----0.00-103.09-104.18-111.07-111.05------------0.00------19.41------
Protagenic Therapeutics Inc0.00-3.93m8.07m----1.90-----0.9072-0.90720.000.95880.00-------57.36-81.23-66.24-106.78------------0.0918------21.39------
Kazia Therapeutics Ltd (ADR)14.74k-13.37m8.27m12.00--0.9086--561.09-0.8109-0.81090.00080.34530.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Cannabis Bioscience Internatnl Hlgs Inc56.94m6.94m8.31m389.000.00150.00020.90030.14590.53280.53284.294.920.591762.811.45146,384.307.83--11.73--31.96--13.24--0.685650.750.0631--12.79--177.84------
Theriva Biologics Inc0.00-18.46m8.31m21.00--0.2007-----1.18-1.180.002.570.00----0.00-26.32-42.49-31.20-46.29------------0.0049------13.64---11.36--
Data as of Mar 28 2024. Currency figures normalised to Gamida Cell Ltd's reporting currency: US Dollar USD

Institutional shareholders

23.30%Per cent of shares held by top holders
HolderShares% Held
Levin Capital Strategies LPas of 08 Feb 20249.13m6.88%
Fidelity Management & Research Co. LLCas of 31 Dec 20237.61m5.74%
Meitav Mutual Funds Ltd.as of 31 Dec 20233.66m2.76%
Millennium Management LLCas of 31 Dec 20232.57m1.94%
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Ltd.as of 31 Dec 20232.21m1.67%
ARK Investment Management LLCas of 31 Dec 20232.14m1.62%
Mariner LLCas of 31 Dec 20231.02m0.77%
Renaissance Technologies LLCas of 31 Dec 2023957.58k0.72%
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet Ltd.as of 31 Dec 2023801.84k0.61%
Nantahala Capital Management LLCas of 31 Dec 2023800.00k0.60%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.